Literature DB >> 23190780

Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements.

Ilona Sarasoja1, Jukka Jokinen, Mika Lahdenkari, Terhi Kilpi, Arto A Palmu.   

Abstract

BACKGROUND: We have previously shown that the 7-valent pneumococcal conjugate vaccine (PncCRM) given in infancy is effective in reducing tympanostomy tube placements up to 4 to 5 years of age. This study aimed to assess the effectiveness of pneumococcal conjugate vaccines PncCRM and PncOMPC from 2 up to 13 years of age.
METHODS: Altogether 2497 children participated in the Finnish Otitis Media Vaccine trial conducted in 1995 to 1999 and were vaccinated at 2, 4, 6 and 12 months of age with PncCRM or PncOMPC or hepatitis B vaccine as controls. The data for tympanostomy tube placements were collected from health registers including hospital and private office operations. Vaccine efficacy was estimated by comparing incidences of tympanostomies from 2 to 12-13 years of age in each of the pneumococcal vaccine groups with the control group.
RESULTS: Register data were searched for 2474 subjects. A total of 535 tympanostomy tube placements were identified in the health registers from 1998 through 2008 with a cumulative incidence of 14.6% from 2 to 13 years of age in the control group. The vaccine impact was age-dependent: from 2 through 5 years of age the vaccine effectiveness was 34% (95% confidence interval: 1% to 52%) for PncCRM and 6% (-28 to 31) for the PncOMPC vaccine. For the age group of 6 to 12-13 years the vaccine effectiveness estimates for the PncCRM and PncOMPC groups were -13% (-137 to 46) and -2% (-123 to 54), respectively.
CONCLUSIONS: PncCRM vaccine reduced the tympanostomy tube placements up to 5 years of age. No impact on new surgical procedures could be demonstrated after that but the benefit achieved was sustained.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23190780     DOI: 10.1097/INF.0b013e31827c9bcc

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  A Cation-Binding Surface Protein as a Vaccine Antigen To Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Antoinette Johnson; Gregory E Wilding; Mary Koszelak-Rosenblum; Michael G Malkowski
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

Review 2.  Panel 6: Vaccines.

Authors:  Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 3.497

3.  Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media.

Authors:  Isabelle Hau; Corinne Levy; Laurence Caeymaex; Robert Cohen
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

4.  Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Daniel M Weinberger; Marc Lipsitch; Ron Dagan
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

5.  Pneumococcal conjugate vaccines for preventing acute otitis media in children.

Authors:  Alexandre C Fortanier; Roderick P Venekamp; Chantal Wb Boonacker; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux
Journal:  Cochrane Database Syst Rev       Date:  2019-05-28

6.  Pneumococcal conjugate vaccines for preventing acute otitis media in children.

Authors:  Joline Lh de Sévaux; Roderick P Venekamp; Vittoria Lutje; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux
Journal:  Cochrane Database Syst Rev       Date:  2020-11-24

7.  Association of pneumococcal conjugate vaccination with rates of ventilation tube insertion in Denmark: population-based register study.

Authors:  Christina Groth; Reimar W Thomsen; Therese Ovesen
Journal:  BMJ Open       Date:  2015-06-05       Impact factor: 2.692

8.  Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines.

Authors:  Hyunju Lee; Eun Hwa Choi; Hoan Jong Lee
Journal:  Korean J Pediatr       Date:  2014-02-24

9.  Pneumococcal conjugate vaccines reduce myringotomy with tympanostomy tube insertion in young children in Japan.

Authors:  Yui Ogawa; Masaru Kunimoto; Sachio Takeno; Toru Sonoyama; Takashi Ishino; Takao Hamamoto; Tsutomu Ueda
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-12-11

10.  Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control.

Authors:  Dominic Thorrington; Nick Andrews; Julia Stowe; Elizabeth Miller; Albert Jan van Hoek
Journal:  BMC Med       Date:  2018-02-08       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.